{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:45:34Z","timestamp":1790300734940,"version":"4.1.0"},"reference-count":30,"publisher":"National Academy of Sciences","issue":"45","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2010,11,9]]},"abstract":"<jats:p>A unique multicomponent vaccine against serogroup B meningococci incorporates the novel genome-derived proteins fHbp, NHBA, and NadA that may vary in sequence and level of expression. Measuring the effectiveness of such vaccines, using the accepted correlate of protection against invasive meningococcal disease, could require performing the serum bactericidal assay (SBA) against many diverse strains for each geographic region. This approach is impractical, especially for infants, where serum volumes are very limited. To address this, we developed the meningococcal antigen typing system (MATS) by combining a unique vaccine antigen-specific ELISA, which detects qualitative and quantitative differences in antigens, with PorA genotyping information. The ELISA correlates with killing of strains by SBA and measures both immunologic cross-reactivity and quantity of the antigens NHBA, NadA, and fHbp. We found that strains exceeding a threshold value in the ELISA for any of the three vaccine antigens had \u226580% probability of being killed by immune serum in the SBA. Strains positive for two or more antigens had a 96% probability of being killed. Inclusion of multiple different antigens in the vaccine improves breadth of coverage and prevents loss of coverage if one antigen mutates or is lost. The finding that a simple and high-throughput assay correlates with bactericidal activity is a milestone in meningococcal vaccine development. This assay allows typing of large panels of strains and prediction of coverage of protein-based meningococcal vaccines. Similar assays may be used for protein-based vaccines against other bacteria.<\/jats:p>","DOI":"10.1073\/pnas.1013758107","type":"journal-article","created":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T23:15:59Z","timestamp":1287616559000},"page":"19490-19495","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":266,"title":["Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines"],"prefix":"10.1073","volume":"107","author":[{"given":"John","family":"Donnelly","sequence":"first","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boccadifuoco","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Biolchi","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ward","sequence":"additional","affiliation":[{"name":"Center for Vaccine Research, School of Medicine, University of California Los Angeles, Torrance, CA 90505;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Frasch","sequence":"additional","affiliation":[{"name":"Frasch Biologics Consulting, Martinsburg, WV 25402;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Richard","family":"Moxon","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, John Radcliffe Hospital, Oxford University, Oxford OX3 9DU, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stella","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Andrews","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Emeryville, CA 94608; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Emeryville, CA 94608; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Santos","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santini","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Boucher","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Serruto","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia Monica","family":"Giuliani","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, 53100 Siena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61016-2"},{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.091"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0906357"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03594-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90091-W"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01251-4"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.063"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00039-07"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne J","year":"1987","unstructured":"J Finne, D Bitter-Suermann, C Goridis, U Finne, An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 138, 4402\u20134407 (1987).","journal-title":"J Immunol"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1327"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1367"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1385"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.014"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915162107"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/379375"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00033-08"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2958.2004.04423.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00591-1"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.058"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00341-07"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000710"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/424464"},{"key":"e_1_3_3_30_2","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow R","year":"2005","unstructured":"R Borrow, et al., Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 12, 970\u2013976 (2005).","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1013758107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T18:46:57Z","timestamp":1685818017000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1013758107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":30,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2010,11,9]]}},"alternative-id":["10.1073\/pnas.1013758107"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1013758107","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]},"assertion":[{"value":"2010-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}